Quarterly Updates14 May 2026, 04:00 pm
Senores Pharma: No Deviation in IPO Funds for Q4 FY26
AI Summary
Senores Pharmaceuticals Ltd reported no deviation or variation in the utilization of funds raised through its IPO for the quarter ended March 31, 2026. The IPO raised ₹500 Crores. While some delays occurred in deploying funds for the Havix subsidiary due to geopolitical issues, the company received management approval to utilize the funds by Fiscal 2027. The audit committee and board of directors reviewed and approved the statement on May 14, 2026.
Key Highlights
- Senores Pharma reports no deviation in IPO fund utilization for Q4 FY26.
- IPO raised ₹500 Crores on December 26, 2024.
- Delay in Havix subsidiary investment due to geopolitical issues; utilization extended to FY27.
- Audit Committee and Board approved the statement on May 14, 2026.
Price Impact
More from SENORES